Citing free speech, ex-Intermune CEO asks top court to weigh his wire-fraud conviction

The former CEO of InterMune ($ITMN), Scott Harkonen, who was convicted of wire fraud for issuing a misleading press release about one of the company's drugs, has asked the U.S. Supreme Court to review whether prosecutors violated his First Amendment rights. Report

Suggested Articles

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.